65,437 trials
Type 1 Diabetes Mellitus-Type 2 Diabetes Mellitus
Primary: Change in Glycated Hemoglobin A1c (HbA1c) From Baseline to Week 26 — -0.38; -0.30 percentage of HbA1c
Hepatic Impairment
Primary: Maximum Plasma Concentration (Cmax) of PF-05221304 — 1220; 1591; 1433; 1592 Nanogram per milliliter (ng/mL)
Peptic Ulcer
Primary: Number of Participants With Ulcer Recurrence — 1; 7 participants
PTSD · Alcoholism
Primary: Clinician Administered PTSD Scale (CAPS) — 43.2; 42.1; 25.8; 32.9 score on a scale — p=.002
Arthroplasty, Replacement, Knee · Pain, Postoperative
Primary: 10 Meter Walk Test — 38.6; 49.8; 43.3 Seconds
Erectile Dysfunction
Primary: Number of Participants With Adverse Experiences as Measured by Changes in Physical Examination of the Penis — 0; 0; 0 Participants
Peritoneal Dialysis (PD) · Anemia · Chronic Kidney Disease
Primary: Pharmacokinetics (PK) of Triferic Iron Administered in Patients on Chronic Peritoneal Dialysis: Maximum Concentration (Cmax) of Serum Total Iron After Intraperitoneal…
Pain
Primary: Pain at Time of Uterine Evacuation — 63.79; 62.21; 64.58; 66.12 score on a scale
Healthy Volunteers
Primary: Cmax: Maximum Observed Plasma Concentration for Alogliptin and Pioglitazone — 165.3; 154.9; 162.3; 157.4 nanogram per milliliter (ng/ml) — p=0.014
Recurrent Melanoma · Stage IIIB Melanoma · Stage IIIC Melanoma
Primary: Overall Response Rate in "High Affinity" Group — 0.5 Proportion of participants
Infant,Premature · Feeding; Difficult, Newborn
Primary: Caregiver Satisfaction [Immediate] — 82; 67 participants
Prostate Cancer Metastatic
Primary: Overall Survival — 34.4; 33.2; 34.3 Months — p=0.4742
Carcinoma, Non-Small-Cell Lung
Primary: Percentage of Patients With Adverse Drug Reactions (ADR) by Severity Class. — 21.02; 21.13; 44.59; 57.75 Percentage of patients (%)
Central Nervous System Tumors
Primary: Measurement of Number of Adverse Events — 4; 6; 3; 5 Adverse events
Prostate Cancer
Primary: Safety of Balloon Implant — 0 Participants